×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABT – abbott laboratories (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/1
10:12 pm
abt
????????????????:2026???2036????CAGR10.01%?50.8??????????? [CNET News]
Low
Report
????????????????:2026???2036????CAGR10.01%?50.8??????????? [CNET News]
4/1
01:08 pm
abt
Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) [Seeking Alpha]
Low
Report
Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) [Seeking Alpha]
4/1
06:50 am
abt
Whoop concludes $575m fundraise, adding Abbott as strategic investor [Yahoo! Finance]
Low
Report
Whoop concludes $575m fundraise, adding Abbott as strategic investor [Yahoo! Finance]
4/1
01:52 am
abt
This Dividend King Is Down 26%. When Will It Bounce Back? [Yahoo! Finance]
Low
Report
This Dividend King Is Down 26%. When Will It Bounce Back? [Yahoo! Finance]
3/31
05:45 pm
abt
WHOOP Health Platform Gets Glitzy Investors, Makes Big Promises [Yahoo! Finance]
Low
Report
WHOOP Health Platform Gets Glitzy Investors, Makes Big Promises [Yahoo! Finance]
3/31
05:27 pm
abt
WHOOP Health Platform Gets Glitzy Investors, Makes Big Promises [Forbes]
Low
Report
WHOOP Health Platform Gets Glitzy Investors, Makes Big Promises [Forbes]
3/31
04:49 pm
abt
Whoop Raises $575 Million at $10.1 Billion Valuation, Reports 103% Growth [Yahoo! Finance]
Low
Report
Whoop Raises $575 Million at $10.1 Billion Valuation, Reports 103% Growth [Yahoo! Finance]
3/31
08:02 am
abt
Abbott Laboratories (ABT) had its price target lowered by BTIG Research from $140.00 to $131.00. They now have a "buy" rating on the stock.
Low
Report
Abbott Laboratories (ABT) had its price target lowered by BTIG Research from $140.00 to $131.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
05:32 pm
abt
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Stratton John G
Low
Report
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Stratton John G
4/2
05:24 pm
abt
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Roman Michael F
Low
Report
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Roman Michael F
4/2
05:16 pm
abt
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Gonzalez Patricia Paola
Low
Report
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Gonzalez Patricia Paola
4/2
05:07 pm
abt
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Alpern Robert J
Low
Report
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Alpern Robert J
4/2
05:01 pm
abt
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Ahuja Nita
Low
Report
Form 4 ABBOTT LABORATORIES For: Mar 31 Filed by: Ahuja Nita
3/26
03:06 pm
abt
Form SCHEDULE 13G/A ABBOTT LABORATORIES Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A ABBOTT LABORATORIES Filed by: VANGUARD GROUP INC
3/25
06:57 pm
abt
Form 4 ABBOTT LABORATORIES For: Mar 23 Filed by: ORVILLE JACOB A
Low
Report
Form 4 ABBOTT LABORATORIES For: Mar 23 Filed by: ORVILLE JACOB A
3/25
06:47 pm
abt
Form 3 ABBOTT LABORATORIES For: Mar 23 Filed by: ORVILLE JACOB A
Low
Report
Form 3 ABBOTT LABORATORIES For: Mar 23 Filed by: ORVILLE JACOB A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Abbott Labs Is Sliding Closer To Attractive Territory [Seeking Alpha]
10.0%
3/16 Form 4 ABBOTT LABORATORIES For: Mar 13 Filed by: Boudreau Philip P 6.6%
3/27 Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes 6.4%
4/16 Form 8-K ABBOTT LABORATORIES For: Apr 16 5.6%
3/1 The Best Dividend Aristocrat You Can Buy Right Now [The Motley Fool] 5.4%
3/3 Form 4 ABBOTT LABORATORIES For: Feb 28 Filed by: Wainer Andrea F 5.2%
3/9 Form 3 ABBOTT LABORATORIES For: Mar 01 Filed by: Boudreau Philip P 5.0%
4/8 Abbott's FreeStyle® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic 4.7%
4/13 Fed Circuit orders new trial in Abbott drug test patent case [Reuters] 4.2%
4/3 UPDATE 2-Anyone near Trump or Pence will be given rapid coronavirus test - White House [Reuters] 4.1%
3/16 Form 4 ABBOTT LABORATORIES For: Mar 13 Filed by: Boudreau Philip P 6.6%
3/27 Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes 6.4%
4/16 Form 8-K ABBOTT LABORATORIES For: Apr 16 5.6%
3/1 The Best Dividend Aristocrat You Can Buy Right Now [The Motley Fool] 5.4%
3/3 Form 4 ABBOTT LABORATORIES For: Feb 28 Filed by: Wainer Andrea F 5.2%
3/9 Form 3 ABBOTT LABORATORIES For: Mar 01 Filed by: Boudreau Philip P 5.0%
4/8 Abbott's FreeStyle® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic 4.7%
4/13 Fed Circuit orders new trial in Abbott drug test patent case [Reuters] 4.2%
4/3 UPDATE 2-Anyone near Trump or Pence will be given rapid coronavirus test - White House [Reuters] 4.1%
TOP News Decliners
3/18
Associated Press: Cancer and heart surgeries now delayed as coronavirus alters care [MarketWatch]
-10.8%
3/13 Form DEF 14A ABBOTT LABORATORIES For: Apr 24 -10.6%
3/22 You Won't Regret Buying These 3 Bargain Stocks [The Motley Fool] -9.8%
3/19 Africa coronavirus cases to rise as some undetected - Africa's CDC [Reuters] -8.7%
2/3 Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke -5.4%
2/25 The Real Earnings Season Starts Now: Time To Read The Footnotes [Forbes] -4.4%
3/27 Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Morgan Stanley from $101.00 to $96.00. They now have an "overweight" rating on the stock. -3.7%
3/31 Phase 4 Coronavirus Infrastructure Spending To Start At $2 Trillion [Forbes] -3.7%
8/13 Form 4 ABBOTT LABORATORIES For: Aug 09 Filed by: Funck Robert E -3.5%
3/10 Form 4 ABBOTT LABORATORIES For: Mar 06 Filed by: Watkin Jared -3.4%
3/13 Form DEF 14A ABBOTT LABORATORIES For: Apr 24 -10.6%
3/22 You Won't Regret Buying These 3 Bargain Stocks [The Motley Fool] -9.8%
3/19 Africa coronavirus cases to rise as some undetected - Africa's CDC [Reuters] -8.7%
2/3 Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke -5.4%
2/25 The Real Earnings Season Starts Now: Time To Read The Footnotes [Forbes] -4.4%
3/27 Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Morgan Stanley from $101.00 to $96.00. They now have an "overweight" rating on the stock. -3.7%
3/31 Phase 4 Coronavirus Infrastructure Spending To Start At $2 Trillion [Forbes] -3.7%
8/13 Form 4 ABBOTT LABORATORIES For: Aug 09 Filed by: Funck Robert E -3.5%
3/10 Form 4 ABBOTT LABORATORIES For: Mar 06 Filed by: Watkin Jared -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: